PIMAGEDINE IN PATIENTS WITH TYPE 2 OVERT DIABETIC NEPHROPATHY

吡马地定治疗 2 型显性糖尿病肾病患者

• 批准号: 6113729
• 负责人: JOHN E GERICH
• 金额: $ 1.48万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113729
• 关键词: clinical research; clinical trials; diabetes mellitus therapy; diabetic nephropathy; human subject; human therapy evaluation; hypoglycemic agents; inhibitor /antagonist; kidney disorder chemotherapy; kidney function; noninsulin dependent diabetes mellitus; outcomes research

The objective of this study are to evalute the safety and efficacy of Pimagedine in preserving renal function in patients with type 2 diabetes mellitus and overty diabetic nephropahty. The effects of pimagedine on protein crosslinking, all-cause mortality, and cardiovascular mortality and morbidity will be assessed.

本研究的目的是评价匹马定对2型糖尿病合并糖尿病肾病患者肾功能保护的有效性和安全性。 将评估匹马定对蛋白质交联、全因死亡率以及心血管死亡率和发病率的影响。